Health Secretary Robert F. Kennedy Jr.’s department has pushed a peptides “interim access policy” to the White House, a move aimed at letting specialty pharmacies temporarily make some of the most sought after peptide drugs.
NBC News reported that Kennedy’s Department of Health and Human Services submitted the plan to the Office of Management and Budget, with a related posting appearing Thursday on a government website. HHS officials did not immediately respond to comment requests Thursday afternoon.
The filing itself does not spell out every detail. Two people familiar with the plan, speaking on condition of anonymity about confidential deliberations, said the intent is to let pharmacies temporarily compound popular peptides, including BPC-157, under enforcement discretion. That approach would signal the Food and Drug Administration will selectively choose not to enforce some of its own rules against producing certain peptides.
Compounding pharmacies mix customized medications that traditional drugmakers do not supply. Under the described plan, those specialty pharmacies would gain clearer room to produce selected peptides without fearing immediate enforcement action.
Formal addition of peptides to the FDA’s list of drugs treated as safe for compounding would require federal rulemaking. That process can take years and multiple rounds of public comment. It is not immediately clear whether the administration still plans to pursue that longer track.
Wall Street analysts estimate the peptide market could reach $2 billion to $3 billion. Major telehealth firms Hims & Hers and Noom recently announced plans to offer peptides to customers if the federal government eases access.
Before joining the administration, Kennedy declared that the “FDA’s war” on peptides and other wellness products would soon end. After taking office as health secretary, he argued U.S. compounding pharmacies must be allowed to sell peptides because Americans were turning to “gray market” products made in China and other countries.
Those overseas products have also surfaced on online platforms such as TikTok. Kennedy framed domestic compounding access as a way to pull demand away from that unregulated pipeline.
Earlier this year, he directed the agency to reconsider a short list of chemicals widely promoted by wellness influencers and fitness celebrities. Unproven peptide products have been popular inside the Make America Healthy Again movement, and some of the biggest MAHA figures sell peptide injections and supplements.
The FDA had previously placed BPC-157 and more than a dozen other injectable peptides on its list of substances too risky to be compounded. Agency staff scientists reiterated that none of the peptides had been studied enough to establish safety and effectiveness. Most available data comes from animal studies.
Possible risks cited by the FDA include contamination, allergic reactions, and tumor growth. The products’ uses are not FDA approved.
In July, a panel of external FDA advisers recommended that the agency drop restrictions on six of the seven peptides put before them. That advice ran against the scientific conclusion of FDA staff scientists.
Brigham Buhler, a wellness clinic operator who sells peptides through an online service and is described as a Kennedy ally, praised the proposal on X.
“This isn’t about whether you’re for or against peptides. It’s about whether you’re for or against MEDICAL FREEDOM.”
Buhler also called the development huge. His reaction captures the political charge around the policy: supporters cast wider pharmacy access as a freedom issue, while the FDA’s prior risk listings and staff science warnings remain on the record.
OMB reviews federal rules and regulations that may carry significant economic impact. The peptides plan now sits in that White House review channel.
Investigators and reviewers will need to determine the final scope of any enforcement discretion, including which peptides beyond BPC-157 qualify and how long temporary compounding permission would last. Authorities have not publicly released the full policy text through the White House filing described in the reporting.
Officials also have not said whether they will still seek formal rulemaking to place peptides on the compounding safe list, a path that could lock in longer term legal certainty but would move far more slowly than interim discretion.
Until those answers surface, compounding pharmacies, telehealth companies, and patients face a transitional posture: a submitted access plan, a prior FDA risk list, a split between outside advisers and staff scientists, and no final published rule.
Enforcement discretion is not the same as FDA approval. It is a choice about when the agency will act. That distinction matters for patients chasing recovery, performance, or wellness claims built largely on animal data and influencer promotion.
It also matters for institutions. Kennedy’s HHS has moved a concrete filing to OMB after months of public pressure to end what he called the FDA’s war on peptides. The July adviser panel already recommended easing limits on most peptides it reviewed. Staff scientists still hold that the safety and effectiveness case is incomplete.
HHS silence on Thursday afternoon left the public with the government website posting, the anonymous description of temporary compounding for popular peptides, and the known business interest from firms ready to sell if access opens.
When Washington loosens the grip on contested medical products, the test is simple: protect lawful access and honest compounding without abandoning basic safety duty. Voters can live with debate. They cannot live with agencies that hide the ball or markets that outrun the law.
